Specifically, miR-146a limits PGE2 levels within IECs through two distinct mechanisms: (1) by limiting IL-17R-TRAF6-induced Cox-2 levels and (2) by directly inhibiting PTGES2, an enzyme that converts PGH2 to PGE248, to confer CRC resistance. Here, TRAF6 is linked to colorectal carcinoma.